^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

BI-2493

i
Other names: BI-2493
News
Trials
Company:
Boehringer Ingelheim
Drug class:
pan-KRAS inhibitor
News
Trials